BioHarvest Sciences Inc. (BHST)

Nasdaq: BHST · Pharmaceutical Preparations · Vancouver, BC · filing with the SEC since 2017

Full chart Alerts Compare

Grade6.1

◀ Past 7.0● Present 5.6▶ Future 5.9

3 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$34.5M+37.0%

Net income-$11.1M+13.8%

Earnings per share$-0.60+25.0%

Operating cash flow-$7.2M-8.1%

Cash$23.0M+863.4%

Debtn/a

Shareholders’ equity$25.4M+1813.4%

Shares, dilutedn/a

Return on equity-43.8%

The recordfrom its filings

Filings in 202633

Newest filingNov 12 · 6-K

Annual reportMar 31, 2026

Quarterly reportn/a

Next report due40-F by Apr 30

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents grantedn/a

Filer category<br>Emerging growth company

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Oct 29, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Oct 13, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Oct 8, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Oct 2, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 15, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 15, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 14, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 3, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Aug 12, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

BioHarvest Sciences Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Vancouver, BC.

Newest on the record

Interim report, foreign filer on Nov 12. Before it, interim report, foreign filer on Oct 29.

What is due next

The 40-F for the period to Dec 31, 2026, due by Apr 30, 2027.

About BHST

BioHarvest Sciences Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Vancouver, BC. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $35 million and a loss of $11 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersVancouver, BC

Business modelPre-revenue company

ExchangeNasdaq

Filing since2017

Fiscal year endsDec 31

SEC number (CIK)1723464

Peers on fileATOS, AKTX, VTGN, UNCY

Who runs it

Financial performance

In fiscal 2025 BioHarvest Sciences’s revenue was $34.51 million, up 37.0% from $25.19 million the year before. It made a net loss of $11.13 million.

Annual report, filed Mar 31, 2026.

Financial statements

The grade

BioHarvest Sciences grades 6.1 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Six of the nine metrics are read as filed and three are SI estimates, each with its reasoning.

◀ Past7.0

● Present5.6

▶ Future5.9

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton BHST · research, not advice